Major Depressive Disorder, Recurrent, Unspecified Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
Objectives
- To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in
healthy subjects.
- To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.
This will be a randomized, double-blind, placebo-controlled, multiple ascending dose study to be conducted in the US. Approximately 48 healthy subjects will be enrolled into one of the four groups ;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01894815 -
Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial
|
Phase 3 | |
Completed |
NCT01361815 -
Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor(SSRI)
|
N/A | |
Completed |
NCT01569711 -
Deep Brain Stimulation of Nucleus Accumbens for Chronic and Resistant Major Depressive Disorder
|
N/A |